Hodgkin Disease: all 914 studies
Page 5 of 10. Open to participants first (136), then studies with results posted, then the rest; newest registration first within each.
- Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin LymphomaActive, not recruitingNCT06761599
- A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)TerminatedNCT06761586Phase 1
- Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With LymphomaActive, not recruitingNCT06744075Not applicable
- ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisSuspendedNCT06680661Phase 2
- Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma PatientsCompletedNCT06564259
- A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingNCT06521567Phase 1/2
- Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.CompletedNCT06295211
- A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersTerminatedNCT06254495Phase 1
- Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)CompletedNCT06235047
- Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin LymphomaCompletedNCT06190457
- Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer SurvivorsCompletedNCT06171945Not applicable
- A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1
- A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy AloneWithdrawnNCT06104878
- Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HDCompletedNCT06093334Not applicable
- Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer SurvivorsActive, not recruitingNCT06002828
- Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2
- Integrated Actionable Aging Assessment for Cancer Patients PilotActive, not recruitingNCT05871008Not applicable
- Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's LymphomaStatus unknownNCT05772624Phase 2
- Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaActive, not recruitingNCT05723055Phase 2
- A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3
- Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma PatientsStatus unknownNCT05663983
- Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaStatus unknownNCT05660993Phase 2
- First in Human, Dose Escalation, Dose Expansion Study of AUR105TerminatedNCT05605119Phase 1
- Improving Exercise Capacity With a Tailored Physical Activity InterventionActive, not recruitingNCT05595577Not applicable
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesActive, not recruitingNCT05589896Phase 1/2
- Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingNCT05565417Phase 1/2
- STAY-STRONG Study of Exercise Training During ChemotherapyCompletedNCT05556239Not applicable
- Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood CancerCompletedNCT05550948Not applicable
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell TransplantActive, not recruitingNCT05540340Phase 1
- Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete RemissionActive, not recruitingNCT05502250Phase 2
- Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin LymphomaStatus unknownNCT05490953Phase 4
- Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of LymphomaCompletedNCT05410314
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
- Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline TherapyActive, not recruitingNCT05352828Phase 1
- Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and LymphomaActive, not recruitingNCT05346809Phase 2
- A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersSuspendedNCT05337735Phase 2
- Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsActive, not recruitingNCT05300282Phase 1/2
- Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma PatientsStatus unknownNCT05254821
- Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS TrialCompletedNCT05205512Not applicable
- Fitness Assessment in Young Adults Recovered From LymphomaCompletedNCT05188755Not applicable
- PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaStatus unknownNCT05137886Phase 2
- (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).WithdrawnNCT05134740Phase 1
- The BurnAlong Pilot Study for Adolescent and Young Adult Cancer SurvivorsCompletedNCT05131815Not applicable
- Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse EventsCompletedNCT05123001
- Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical TrialCompletedNCT05066555
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
- Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin LymphomaActive, not recruitingNCT05019976Not applicable
- A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotinCompletedNCT04998331
- A Survey Exploring Health and Screening Tests in People Treated for Hodgkin LymphomaCompletedNCT04996862
- Lung Screening in People Cured of Hodgkin LymphomaCompletedNCT04986189Not applicable
- A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04981899Phase 1/2
- Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive LymphomasWithdrawnNCT04952584Phase 1
- Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's LymphomaStatus unknownNCT04893538
- Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDGActive, not recruitingNCT04892667Not applicable
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosisTerminatedNCT04758650Phase 2
- CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin LymphomaActive, not recruitingNCT04726501Phase 4
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
- A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.Active, not recruitingNCT04671693Not applicable
- CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.Status unknownNCT04653649Phase 1/2
- Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaCompletedNCT04640779Phase 1
- Physical Capacity in Hodgkin Lymphoma SurvivorsCompletedNCT04636255Not applicable
- Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTCompletedNCT04629430Not applicable
- Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.TerminatedNCT04621604Not applicable
- Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
- Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
- Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
- Interest of a Systematic One-year Monitoring by 18F-FDG PET-CTCompletedNCT04464590
- Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin LymphomaStatus unknownNCT04419441
- Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative StudyCompletedNCT04396119
- Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaWithdrawnNCT04373083Phase 2
- Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin LymphomaStatus unknownNCT04342936Phase 3
- Follow Up of High Risk Hodgkin Lymphoma in First Complete RemissionCompletedNCT04298619
- Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-GlucoseCompletedNCT04292626Phase 1
- Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive LymphomasActive, not recruitingNCT04288726Phase 1
- Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)Active, not recruitingNCT04268706Phase 2
- Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin LymphomaStatus unknownNCT04239170Phase 2
- Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04134325Early Phase 1
- Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)CompletedNCT04091490Phase 2
- Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic CancersTerminatedNCT04072393Not applicable
- A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard ChemotherapyStatus unknownNCT04044222Phase 3
- FLT PET: A Pilot Study in Lymphoma PatientsCompletedNCT04028804
- Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP RegimenStatus unknownNCT04026269Phase 1/2
- Whole-body MRI in Pediatric Hodgkin's LymphomaCompletedNCT04005703
- CBT on Fatigue in Survivors of Hodgkin LymphomaCompletedNCT03968250Not applicable
- A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian FederationCompletedNCT03942263
- Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory LymphomaStatus unknownNCT03921879Phase 1
- Compassionate Use Re-Infusion of ATLCAR.CD30No longer availableNCT03914885
- Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)CompletedNCT03904134Not applicable
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaActive, not recruitingNCT03843294Phase 1
- Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR)CompletedNCT03838627
- A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaStatus unknownNCT03800706Phase 2
- Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HLCompletedNCT03766516
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantActive, not recruitingNCT03739502Phase 2
- Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin LymphomaCompletedNCT03730363Phase 1
- A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin LymphomaCompletedNCT03722147Phase 1/2